Brought to you by 
BMS to develop and market PDL's multiple myeloma antibody
16 Nov 2021
Executive Summary
PDL BioPharma (oncology and immune disease antibodies) has licensed Bristol-Myers Squibb worldwide rights to its Phase I CS1-targeting antibody elotuzumab for multiple myeloma.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
BMS to develop and market PDL's multiple myeloma antibody
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice